Instylla Stock

www.instylla.com/Healthcare / Medical DevicesFounded: 2017

Instylla is pioneering the development of next-generation liquid embolics for interventional radiology, with a primary focus on interventional oncology and peripheral hemostasis. Based in Bedford, MA, this privately held company is advancing the field through its innovative product, the Embrace™ Hydrogel Embolic System. Designed for controlled, complete, and persistent embolization, Embrace™ aims to significantly improve patient outcomes in these critical clinical areas. Instylla's mission is to restore life, hope, and joy to the world's sickest patients by offering novel embolization solutions that enhance treatment efficacy.

Register To Buy and Sell Shares

For more details on financing and valuation for Instylla, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Instylla’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Instylla.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Instylla investors also invested in these private companies

Catalyst Health Ventures
Sparta Group
AMED Ventures
Excelestar Ventures
Angel Physicians Fund
Delos Capital Partners
Incept

Team

Management Team

Raymond Lareau
President
Amarpreet Sawhney Ph.D
Founder & Chief Executive Officer

Board Members

Darshana Zaveri
Catalyst Health Ventures
Henry Chen JD
Delos Capital Partners
Tara Butler MD
Ascension Ventures
Tasneem Dohadwala
Excelestar Ventures

Frequently Asked Questions About Instylla’s Stock

plusminus
Can you buy Instylla’s stock?
Instylla is not publicly traded on NYSE or NASDAQ in the U.S. To buy Instylla’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Instylla’s stock?
Yes, you can sell stock of a private company like Instylla. Forge can help you sell your Instylla stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Instylla’s stock price?
Instylla is a privately held company and therefore does not have a public stock price. However, you may access Instylla’s private market stock price with Forge Data.
plusminus
What is Instylla’s stock ticker symbol?
Instylla does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Instylla Closes $30M Equity Financing
Instylla, Inc., a Bedford, MA-based company developing next-generation liquid embolics for peripheral vascular embolotherapy, closed a $30m financing round. This round was led by new investor Delos Capital, with continued participation from the investor syndicate of Excelestar Ventures, Ascension Ventures, Catalyst Health Ventures, Amed Ventures, Sparta Group, and Incept, LLC.
Updated on: Apr 20, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.